SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced company highlights and financial results for the first quarter ended March 31, 2015.
“We continue to make substantial progress toward our goal of becoming a leading precision oncology biotechnology company, and we are excited about our potential to develop first-in-class and best-in-class precision medicines to help cancer patients with unmet needs,” said Jonathan Lim, M.D., Chairman and CEO of Ignyta.
Help employers find you! Check out all the jobs and post your resume.
